[go: up one dir, main page]

SK283502B6 - 6-Hydroxy-2-(4-hydroxyfenyl)-3-[4- (2-piperidínetoxy)benzoyl]benzo[b]tiofén hydrochlorid a farmaceutický prostriedok s jeho obsahom - Google Patents

6-Hydroxy-2-(4-hydroxyfenyl)-3-[4- (2-piperidínetoxy)benzoyl]benzo[b]tiofén hydrochlorid a farmaceutický prostriedok s jeho obsahom Download PDF

Info

Publication number
SK283502B6
SK283502B6 SK233-97A SK23397A SK283502B6 SK 283502 B6 SK283502 B6 SK 283502B6 SK 23397 A SK23397 A SK 23397A SK 283502 B6 SK283502 B6 SK 283502B6
Authority
SK
Slovakia
Prior art keywords
benzoyl
benzo
hydroxy
reaction
hydroxyphenyl
Prior art date
Application number
SK233-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK23397A3 (en
Inventor
Elizabeth Smith Labell
Wayne Douglas Luke
Mcgill John Mcneill, Iii
Randal Scot Miller
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK283502(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/308,325 external-priority patent/US5629425A/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SK23397A3 publication Critical patent/SK23397A3/sk
Publication of SK283502B6 publication Critical patent/SK283502B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SK233-97A 1994-09-19 1995-09-19 6-Hydroxy-2-(4-hydroxyfenyl)-3-[4- (2-piperidínetoxy)benzoyl]benzo[b]tiofén hydrochlorid a farmaceutický prostriedok s jeho obsahom SK283502B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/308,325 US5629425A (en) 1994-09-19 1994-09-19 Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US42791495A 1995-04-26 1995-04-26
PCT/US1995/011872 WO1996009045A1 (fr) 1994-09-19 1995-09-19 Composes benzothiophenyle antioestrogeniques

Publications (2)

Publication Number Publication Date
SK23397A3 SK23397A3 (en) 1997-08-06
SK283502B6 true SK283502B6 (sk) 2003-08-05

Family

ID=26976194

Family Applications (1)

Application Number Title Priority Date Filing Date
SK233-97A SK283502B6 (sk) 1994-09-19 1995-09-19 6-Hydroxy-2-(4-hydroxyfenyl)-3-[4- (2-piperidínetoxy)benzoyl]benzo[b]tiofén hydrochlorid a farmaceutický prostriedok s jeho obsahom

Country Status (50)

Country Link
US (4) US6399778B1 (fr)
JP (2) JPH08193081A (fr)
KR (2) KR100367376B1 (fr)
CN (2) CN1075069C (fr)
AP (1) AP754A (fr)
AT (2) AT407988B (fr)
AU (3) AU691955B2 (fr)
BE (2) BE1009625A3 (fr)
BG (1) BG62793B1 (fr)
BR (2) BR9504060A (fr)
CA (2) CA2158399C (fr)
CH (3) CH691478A5 (fr)
CO (2) CO4410190A1 (fr)
CZ (2) CZ290343B6 (fr)
DE (3) DE19534745B4 (fr)
DK (4) DK175903B1 (fr)
EE (1) EE03386B1 (fr)
EG (1) EG23763A (fr)
ES (2) ES2109882B1 (fr)
FI (2) FI121424B (fr)
FR (2) FR2724655B1 (fr)
GB (2) GB2293602B (fr)
GE (1) GEP19991821B (fr)
GR (2) GR1002697B (fr)
HR (2) HRP950482B1 (fr)
HU (2) HU225417B1 (fr)
IE (2) IE80883B1 (fr)
IL (3) IL115315A (fr)
IS (1) IS1788B (fr)
IT (2) IT1277602B1 (fr)
LU (2) LU88661A1 (fr)
LV (2) LV11178B (fr)
MY (1) MY116371A (fr)
NL (2) NL1001196C2 (fr)
NO (2) NO313996B1 (fr)
NZ (2) NZ280027A (fr)
OA (1) OA10406A (fr)
PE (2) PE32796A1 (fr)
PL (2) PL187686B1 (fr)
PT (2) PT101770B (fr)
RO (2) RO115259B1 (fr)
RS (2) RS49578B (fr)
SE (2) SE509265C2 (fr)
SI (2) SI9500293A (fr)
SK (1) SK283502B6 (fr)
TR (1) TR199501136A2 (fr)
TW (1) TW412534B (fr)
UA (2) UA42716C2 (fr)
UY (1) UY24040A1 (fr)
WO (1) WO1996009045A1 (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
CZ300341B6 (cs) 1996-03-26 2009-04-22 Eli Lilly And Company Farmaceutická kompozice obsahující raloxifen
ZA979723B (en) 1996-10-30 1999-07-29 Lilly Co Eli Methods of preventing breast cancer.
CA2236254A1 (fr) * 1997-04-30 1998-10-30 David Warren Hoard Methode de preparation de benzo[b]thiophenes
MXPA01011227A (es) 1999-05-04 2002-07-02 Strakan Ltd Glicosidas androgenas y su actividad androgenica.
AU2002230409A1 (en) * 2000-11-27 2002-06-03 Eli Lilly And Company Process for preparing 3-aryl-benzo(b)thiophenes
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1832582A1 (fr) * 2002-09-30 2007-09-12 A/S GEA Farmaceutisk Fabrik Nouveaux sels d'addition de l'acide raloxifène malonique et/ou leurs solvates et compositions pharmaceutiques les comprenant
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (fr) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, procédés de préparation et leur utilisation en tant que médicaments
HRP20120662T1 (hr) 2004-09-29 2012-09-30 Bayer Pharma Aktiengesellschaft Termodinamički stabilni oblik bay 43-9006 tosilata
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB2456096B (en) * 2006-10-17 2011-08-17 Cipla Ltd Crystalline form of benzothiophene compound and process for preparation thereof
US8258291B2 (en) * 2006-10-25 2012-09-04 Mamtek International Limited Process for the preparation of sucralose by the chlorination of sugar with triphosgene (BTC)
US20080103295A1 (en) * 2006-10-25 2008-05-01 David Losan Ho Process for the preparation of sucrose-6-ester by esterification in the presence of solid superacid catalyst
DE102007032451B4 (de) 2007-07-12 2010-09-30 Icfs Gmbh Verfahren zur Herstellung von aromatischen Ketonen
WO2009015004A1 (fr) * 2007-07-20 2009-01-29 King Pharmaceuticals Research And Development, Inc. Cristaux de (2-amino-4,5,6,7-tétrahydrobenzo[b]thién-3-yl)(4-chlorophényl)méthanone
EP3098223A1 (fr) 2007-08-03 2016-11-30 Boehringer Ingelheim International GmbH Forme cristalline d'un dérivé de dihydroptéridione
WO2009080364A1 (fr) * 2007-12-21 2009-07-02 Synthon B.V. Composition de raloxifène
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2307399B1 (fr) * 2008-06-09 2016-05-18 ERREGIERRE S.p.A. Procédé de régulation de la croissance d'un cristal de chlorhydrate de raloxifène
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
EP2344195A2 (fr) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Polythérapie pour le traitement du diabète et des états pathologiques apparentés
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
NZ592924A (en) 2008-12-23 2014-05-30 Boehringer Ingelheim Int Salt forms of a xanthine derivative
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2448562B1 (fr) 2009-07-02 2013-11-06 Synthon B.V. Composition de raloxifène
EP2314581B1 (fr) 2009-10-23 2012-07-25 Hexal AG Procédé de préparation de dérivés de benzo[b]thiophène
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011099942A1 (fr) 2010-02-09 2011-08-18 Silverstone Pharma Nouveaux sels d'addition de raloxifène, leur procédé de préparation et leur utilisation en thérapie
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
EP3725325B1 (fr) 2010-06-24 2023-05-31 Boehringer Ingelheim International GmbH Traitement du diabète
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
IT1403083B1 (it) * 2010-10-25 2013-10-04 Fidia Farmaceutici Nuova forma polimorfa di raloxifene cloridrato
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
EP2849755A1 (fr) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
ZA201401636B (en) 2013-03-05 2014-11-26 Cipla Ltd Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104496963A (zh) * 2014-12-02 2015-04-08 千辉药业（安徽）有限责任公司 一种盐酸雷洛昔芬的制备方法
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물
KR102815172B1 (ko) * 2020-02-25 2025-05-29 엘지전자 주식회사 히트펌프 및 그 동작방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869485A (en) * 1969-09-25 1975-03-04 Allied Chem Preparation of acid chlorides with phosgene in the presence of a catalyst
GB1456323A (en) * 1974-06-06 1976-11-24 Labaz Benzothiophenes process for preparing them and pharmaceutical compositions containing the same
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
ZA822247B (en) 1981-04-03 1983-11-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
IL65378A (en) * 1981-04-03 1986-02-28 Lilly Co Eli Process for preparing 3-(4-aminoethoxybenzoyl)benzo-(b)thiophenes
US4358593A (en) * 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0062503A1 (fr) 1981-04-03 1982-10-13 Eli Lilly And Company Dérivés de benzothiophène et procédé pour les préparer
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
IL65379A0 (en) * 1981-04-03 1982-05-31 Lilly Co Eli Process for preparing acylated benzothiophenes
DE4117512A1 (de) 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5169860A (en) 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
DE69405491T2 (de) 1993-06-24 1998-02-19 Lilly Co Eli Antiöstrogene 2-Phenyl-3-Aroylbenzothiophene als hypoglykämische Mittel
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5523416A (en) 1994-07-22 1996-06-04 Eli Lilly And Company Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes
CO4410190A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO

Also Published As

Publication number Publication date
SE9503213D0 (sv) 1995-09-15
SI9500292A (en) 1996-06-30
CH691478A5 (de) 2001-07-31
ITMI951935A1 (it) 1997-03-15
JPH08176147A (ja) 1996-07-09
NL1001196A1 (nl) 1996-03-19
KR100381346B1 (ko) 2004-04-13
RS49578B (sr) 2007-04-10
HK1019009A1 (en) 2000-01-14
FI954402L (fi) 1996-03-20
PE14796A1 (es) 1996-05-19
LU88661A1 (fr) 1996-07-15
FR2732020A1 (fr) 1996-09-27
DE19549755B4 (de) 2005-05-04
EE03386B1 (et) 2001-04-16
LV11178A (lv) 1996-04-20
CZ240395A3 (en) 1996-04-17
SE509265C2 (sv) 1998-12-21
IT1277602B1 (it) 1997-11-11
GB2293602A (en) 1996-04-03
HU225417B1 (en) 2006-11-28
HUT74178A (en) 1996-11-28
SE9503214D0 (sv) 1995-09-15
NL1001196C2 (nl) 1997-04-04
ITMI951935A0 (it) 1995-09-15
GB9519032D0 (en) 1995-11-15
FI112226B (fi) 2003-11-14
ES2129293B1 (es) 2000-01-16
IL115314A0 (en) 1996-05-14
CZ292007B6 (cs) 2003-07-16
PL310518A1 (en) 1996-04-01
BG101242A (en) 1998-03-31
ES2129293A1 (es) 1999-06-01
FI954403A7 (fi) 1996-03-20
PT101771A (pt) 1996-04-30
TW412534B (en) 2000-11-21
LV11178B (en) 1996-08-20
JP2860071B2 (ja) 1999-02-24
SI9500293A (en) 1996-06-30
YU61395A (sh) 1998-09-18
DK2897A (da) 1997-01-09
ES2109882B1 (es) 1998-08-16
PT101770B (pt) 1997-04-30
NL1001194A1 (nl) 1996-03-19
NZ280028A (en) 1997-05-26
GB2293382A (en) 1996-03-27
IL115314A (en) 2000-02-29
GR1002709B (el) 1997-06-04
FI954402A0 (fi) 1995-09-18
NO953657D0 (no) 1995-09-15
ATA154295A (de) 2000-12-15
NO308107B1 (no) 2000-07-24
GB2293382B (en) 1998-08-19
IT1277601B1 (it) 1997-11-11
YU61495A (sh) 1998-05-15
FR2724655B1 (fr) 1997-11-14
US20020173645A1 (en) 2002-11-21
NZ280027A (en) 1997-05-26
GB2293602B (en) 1998-05-06
FR2732020B1 (fr) 1997-11-14
NO953657L (no) 1996-03-20
HRP950483A2 (en) 1997-10-31
FI954403A0 (fi) 1995-09-18
KR960010634A (ko) 1996-04-20
HRP950482B1 (en) 2007-04-30
AU692907B2 (en) 1998-06-18
CO4410191A1 (es) 1997-01-09
BE1009626A3 (fr) 1997-06-03
CH691594A5 (de) 2001-08-31
CO4410190A1 (es) 1997-01-09
EG23763A (en) 2007-08-08
IS1788B (is) 2001-11-28
BG62793B1 (bg) 2000-08-31
CH691125A5 (de) 2001-04-30
PT101771B (pt) 1997-04-30
BR9504060A (pt) 1996-09-24
AU691955B2 (en) 1998-05-28
CA2158399A1 (fr) 1996-03-20
NO313996B1 (no) 2003-01-13
IL115315A0 (en) 1995-12-31
UA44240C2 (uk) 2002-02-15
JPH08193081A (ja) 1996-07-30
SK23397A3 (en) 1997-08-06
HRP950483B1 (en) 2003-02-28
HRP950482A2 (en) 1998-02-28
EE9700055A (et) 1997-08-15
CZ240295A3 (en) 1996-04-17
PL187686B1 (pl) 2004-09-30
HUT75033A (en) 1997-03-28
LV11177B (en) 1996-08-20
CA2158400C (fr) 2006-10-24
AP9700938A0 (en) 1997-04-30
AP754A (en) 1999-07-22
LV11177A (lv) 1996-04-20
FI121424B (fi) 2010-11-15
NO953658D0 (no) 1995-09-15
PL182450B1 (pl) 2002-01-31
IS4446A (is) 1997-03-18
PE32796A1 (es) 1996-08-07
SE9503214L (sv) 1996-03-20
ES2109882A1 (es) 1998-01-16
DK175903B1 (da) 2005-06-06
CN1127253A (zh) 1996-07-24
SE9503213L (sv) 1996-03-20
GB9519028D0 (en) 1995-11-15
US5731327A (en) 1998-03-24
IE80883B1 (en) 1999-05-19
RO115259B1 (ro) 1999-12-30
CN1075069C (zh) 2001-11-21
RO115260B1 (ro) 1999-12-30
US6399778B1 (en) 2002-06-04
MY116371A (en) 2004-01-31
ITMI951936A0 (it) 1995-09-15
DK175897B1 (da) 2005-05-30
AU3718695A (en) 1996-04-09
CA2158399C (fr) 2001-03-20
BE1009625A3 (fr) 1997-06-03
CN1132205A (zh) 1996-10-02
TR199501136A2 (tr) 1996-06-21
GEP19991821B (en) 1999-11-05
HU227683B1 (en) 2011-11-28
UY24040A1 (es) 1996-03-07
DK102895A (da) 1996-03-20
CN1068324C (zh) 2001-07-11
KR100367376B1 (ko) 2003-03-06
DK2797A (da) 1997-01-09
PT101770A (pt) 1996-04-30
FR2724655A1 (fr) 1996-03-22
DE19534745A1 (de) 1996-04-04
LU88660A1 (fr) 1996-07-15
AT407988B (de) 2001-07-25
DK102795A (da) 1996-03-20
AU3173095A (en) 1996-04-04
OA10406A (en) 2001-12-05
IL125283A (en) 2001-06-14
UA42716C2 (uk) 2001-11-15
CA2158400A1 (fr) 1996-03-20
AT502957A1 (de) 2007-06-15
WO1996009045A1 (fr) 1996-03-28
IE950721A1 (en) 1996-03-20
RS49513B (sr) 2006-10-27
IL115315A (en) 1999-09-22
ITMI951936A1 (it) 1997-03-15
DK175887B1 (da) 2005-05-23
NL1001194C2 (nl) 1997-04-04
HU9502723D0 (en) 1995-11-28
US6472531B1 (en) 2002-10-29
CZ290343B6 (cs) 2002-07-17
DE19534744A1 (de) 1996-03-21
BR9504059A (pt) 1996-09-24
PL310517A1 (en) 1996-04-01
IE950722A1 (en) 1996-03-20
AU3173195A (en) 1996-04-04
DK175886B1 (da) 2005-05-23
HU9502721D0 (en) 1995-11-28
GR1002697B (el) 1997-05-22
DE19534745B4 (de) 2004-06-09
KR960010637A (ko) 1996-04-20
SE520721C2 (sv) 2003-08-12
NO953658L (no) 1996-03-20

Similar Documents

Publication Publication Date Title
SK283502B6 (sk) 6-Hydroxy-2-(4-hydroxyfenyl)-3-[4- (2-piperidínetoxy)benzoyl]benzo[b]tiofén hydrochlorid a farmaceutický prostriedok s jeho obsahom
US5629425A (en) Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene

Legal Events

Date Code Title Description
MC4A Annulment of patent

Effective date: 20121119